We describe a rapid, specific, and precise analysis for gliclazidein plasma by radial compression,reversed-phase, "high-performance"liquid chromatography.Gliclazide and the internalstandard, 3-chlorogliclazide,are eluted after 4.4 and 6.8 mm, respectively. Only 100 L of plasma and minimal sample workup are required. The limit of detection for gliclazide in plasma is 0.5 mg/L (1.55 mol/L) at 229 nm. Precision (CV) of the assay for 10 and 1 mg of gliclazide per litre is 2.1% and 6.4%, respectively.
Gliclazide (1702E SE; Diamicron), one of the newer sulfonylurea drugs, possesses marked hypoglycemic activity (1) and affects platelet function (2). The drug has a bimodal pattern of absorption in patients, who can thus be considered so-called "fast" and "slow" absorbers, and its elimination half4ife is longer in females than in males (3). As with most drugs, studies of the disposition of gliclazide require assay methods that combine simplicity and specificity with high sensitivity and precision. In addressing this problem, we developed an analytical method for gliclazide in plasma involving radial compres8ion, "high-performance" liquid chromatography (HPLC). Previously, gas chromatography (4), reversed-phase HPLC (5) , and anion-exchange HPLC (6) 
MaterIals and Methods

Apparatus:
We used a modular chromatography system: an M6000A pump (Waters Associates, Inc., Milford, MA 01757), a Model 7125 sample injector (Rheodyne Inc., Berkeley, CA 94710), and a Model 450 variable-wavelength detector (Waters Associates). The columns were a Nova-Pak C15 column (100 mm x 8 miii, 5-nm particle size) in conjunction with a Waters stainless-steel guard column (50 mm x 3.9 mm, packed with Bondapak C18/Corasil, 37-to 50-tim particles) and an RCM-100 radial compression module (Waters Associates). Chromatograins were recorded on a chart recorder (Model R-02; Rikadenki Kogyo, Tokyo, Japan).
Reagents and standards:
A methanolic solution (25 mg/50 mL) of To prepare the mobile phase, add 500 mL of acetonitrile to 500 mL of rapidly stirred 0.05 mol/L potassium dihydrogen orthophosphate (previously adjusted to pH 3 with orthophosphone acid). Filter through a 0.5-tim pore-size ifiter (Miiipore Corp., Bedford, MA 01730) and de-gas by ultrasonication before use. Use reagent-grade water (e.g., Milli-Q, Millipore Corp.) throughout. Use a 2.5 mL/min flow rate and set the detector at 229 nm (0.04 to 0.1 A full-scale), the wavelength maximum for gliclazide in the mobile phase. We determined the precision of the assay by supplementing gliclazide-free plasma with gliclazide to concentrations of 10 and 1 mg/L; these concentrations encompass those measured at steady-state after daily gliclazide doses of 40 to 240 mg in diabetics (3). Aliquots of these samples were stored at -20 #{176}C until assayed. We assayed eight samples of each concentration in no set order, each day for five days. standard of gliclazide in plasma, and plasma from a diabetic patient receiving chronic gliclazide therapy, 2 h after an 80-mg dose. Retention times were 4.4 and 6.8 miii for gliclazide and 3-chlorogliclazide, respectively. The spectral, solvent, and chromatographic properties of 3-chlorogliclazide (7) are similar to those of gliclazide, but N-methylgliclazide, a compound used in the derivatization of gliclazide in gas chromatography (4), can also be used as an internal standard in our HPLC assay.
Results and Discussion
The analysis of gliclazide and the internal standard on the radial compression module gave sharp, symmetrical peaks with baseline resolution and minimal tailing. No endogenous plasma components interfered with the separation. Using a detector attenuation of 0.1 A, we could measure gliclazide concentrations in plasma of 0.5 to 20 mg/L (1.55 to 62 timol/L). Calibration plots of peak-height ratios vs concentration were linear (r> 0.999) over this range. Although concentrations less than 0.5 mg/L may be measured by using higher detector sensitivities and greater injection volumes, others (3) have reported that the hypoglycemic activity of gliclazide is negligible at plasma concentrations less than 0.25 mgfL. To assess assay recovery, we compared the slope of the calibration plot in plasma with the slope of the plot of a similar range of gliclazide concentrations in water (8) . This comparison is valid because no solvent extraction is used in the assay. For concentrations in the 0.5 to 20 mg/L range, analytical recovery of gliclazide was 104%.
Estimates of day-to-day, within-day, and total precision of the assay (Table 1) were calculated from one-way analyses of variance (ovA) of the data, as described previously (9). Program STI-05 on the Texas Instruments SR-52 programmable calculator is well suited for this task because several of the required statistical parameters can be obtained directly from the memory registers once the ANOVA has been completed. The ANOVA approach is preferred to other techniques because all the assay data are used to calculate the within-day, between-day, and total precision (9).
The clinical application of the assay was assessed by measuring plasma gliclazide concentrations in patients who were receiving chronic gliclazide therapy. Blood samples were obtained at 15-mm intervals over 24 h by a continuous sampling device and assayed by HPLC for gliclazide concentration (Figure 2) .
The effect of other drugs on the assay was investigated by comparing their retention times with those of gliclazide and the internal standard. Metformun, furosemide, aimloride, prazosin, methyldopa, and metoprolol are commonly prescribed with gliclazide, and none of these interfered with the assay. In screening a wide selection of other drugs (Table 2) , we found that only warfarin interferes, having a retention time similar to that for gliclazide.
In conclusion, our assay method is simple to perform and is particularly useful when large numbers of samples must be assayed relatively quickly. At least 40 samples can be processed during an 8-h working day. The method is currently being used to study the effects of gliclazide on insulin 
